Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
More Diversity, Multifaceted Outreach Needed in Studies of Genetic Screening for Depression
Three types of salient beliefs were investigated in this study that examined why mothers would or would not participate in depression screening via genetic salivary testing, with the results indicating potential for mental health disparities among diverse populations.
Risk Factors for CRS Plus Asthma Differ Among Younger vs Older Patients
Risk factors as predictors of asthma prevalence among a cohort of patients living with chronic rhinosinusitis (CRS), as they related to age, were evaluated by clinical investigators from the College of Medicine at Korea University.
Dr Anchalee Avihingsanon: We Can Learn About Curing Hepatitis B From Investigating HIV
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial, currently evaluating the responses of treatment-naïve persons living with comorbid HIV/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
SCS Use May Predispose Patients Who Have CRSwNP to Worse Health Outcomes
Using systemic corticosteroids (SCS) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) has been linked to adverse outcomes among patients, prompting these study investigators to compare their health care resource utilization with that of patients who have CRSwNP but don’t use SCS.
Mortality Worsens Following Borderline PH Diagnosis Among Patients With LHF
Following a recent update to the diagnostic criteria for borderline pulmonary hypertension (PH), which is often associated with left heart failure (LHF), outcomes among patients with both conditions remain uncertain.
Dr Anchalee Avihingsanon: We Need More Study on Hep B Endurance in PLWH
The ALLIANCE trial is investigating the responses of treatment-naïve persons living with comorbid HIV (PLWH)/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
Results of Macitentan in PAH From SERAPHIN OL Echo Earlier Trial Safety Data
This open-label extension of the SERAPHIN trial evaluated the long-term safety and tolerability of a small daily dose of the endothelin receptor antagonist against pulmonary arterial hypertension (PAH) among patients from the original study.
Bradykinin Level Displays Biomarker Benefit in Nasal Polyposis
With evidence lacking on the role of inflammation in nasal polyposis (NP), this study investigated the role of 2 potential biomarkers in the nasal secretions of patients who have NP concomitant with aspirin-exacerbated respiratory disease.
Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC
Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Combination Treatment Provides Short-term Endoscopic Relief in CRSwNP Subtype
This study investigated combination treatment of antibiotics plus corticosteroids among persons with aspirin-exacerbated respiratory disease, a subtype of chronic rhinosinusitis with nasal polyposis (CRSwNP).
Adherence to INC Treatment for Nasal Polyposis Remains Low
Despite intranasal corticosteroid (INCs) being a treatment mainstay for chronic rhinosinusitis with nasal polyps, there are ongoing high rates of nonadherence, which can affect treatment efficacy, according to this study’s authors.
Risk of PH Increases With Preterm Birth
Infants born between the 23rd and 25th weeks of pregnancy, classified as extremely low gestational age newborns, are surviving in increasing numbers, note study authors, and with that is growing clinical interest in their long-term sequelae, including pulmonary hypertension (PH).